Carbocistein
CAS number： 2387-59-9
Molecular formula： C5H9NO4S
molecular weight： 179.19
Chemical structure：
Producers shown on SFDA
(Record date:30/09/2021）
Producer | Documents | GMP Valid till(based on SFDA) |
Wuhan Grand Hoyo Co., Ltd. | GMP | Valid till March 2024 |
Guangdong Yishu Pharmaceutical Co., Ltd. | GMP | Valid till January 2019 |
Matrix Laboratories (Xiamen) Ltd. | GMP | Valid till April 2024 |
Linfen Qilin Pharceutical Co., Ltd. | GMP | Valid till March 2021 |
Yichang Sanxia Proudin Biopharmaceutical Co., Ltd. | GMP | Valid till November 2022 |
Renhetang Pharmaceutical Co., Ltd. | GMP | Valid till April 2020 |
Sinopharm Shantou Jinshi Pharmaceutical Co., Ltd. | GMP | Valid till January 2020 |
Yunpeng Pharmaceutical Group Co., Ltd. | GMP | Valid till October 2023 |
Yichang Sanxia Pharmaceutical Co., Ltd. | GMP | Valid till December 2020 |
Producers shown on EP
(Quoted from EP website；record date:30/09/2021）
| Substance | Certificate Holder | Certificate Number | Issue Date | Status | End date | Type |
| Carbocisteine | BACHEM S.A. CH 1895 Vionnaz | R1-CEP 1997-099-Rev 03 | 08/08/2011 | WITHDRAWN BY HOLDER | 22/06/2016 | Chemistry |
| Carbocisteine | Moehs Iberica S.L. ES 08191 Rubi | R1-CEP 1997-037-Rev 06 | 16/04/2019 | VALID | / | Chemistry |
| Carbocisteine | PharmaZell GmbH DE 83064 Raubling | R1-CEP 1998-038-Rev 05 | 19/05/2017 | VALID | / | Chemistry |
| Carbocisteine | WUHAN GRAND HOYO CO., LTD. CN 430 070 Wuhan | R1-CEP 2011-012-Rev 02 | 17/09/2020 | VALID | / | Chemistry |
| Carbocisteine | Bretagne Chimie Fine (BCF) FR 56140 Pleucadeuc | R1-CEP 1997-022-Rev 07 | 14/09/2020 | VALID | / | Chemistry |
Producer:Wuhan Grand Hoyo Co., Ltd. was formerly Wuhan University bioengineering technology company, a former university run enterprise of Wuhan University. In 2008, Yuanda Pharmaceutical (China) Co., Ltd. reached strategic cooperation with Wuhan University and other units through acquisition and reorganization.
The company has a rigorous quality assurance system and has passed ISO 9001, HACCP, fssc22000, SC quality management system certification, China GMP certification, Korea kdmf certification, EU eugmp certification, EU EDQM cos certification, kosher and Halal certification. The product quality of the company meets the international and domestic advanced standards such as CP, USP, BP, EP, Aji and FCC.
Staff size:300-399 persons
Registered capital:RMB 50 million
Producer:Guangdong Yishu Pharmaceutical Co., Ltd. was established in 2000. The company is located in the old plant in Dinghu District, Zhaoqing City, covering an area of 30000 square meters. It has built a solid preparation workshop of 2000 square meters, a chemical synthetic API workshop of 1800 square meters, an office laboratory building of 1600 square meters and a warehouse of 1300 square meters.
Staff size:200-299 persons
Registered capital:RMB 87.7108 million
Producer:Matrix Laboratories (Xiamen) Ltd., established in 2022, is mainly engaged in the production of tablets, hard capsules (including class II psychotropic drugs), granules, APIs and related supporting services.
Staff size:50-99 persons
Registered capital:RMB 178 million 116 thousand and 658
Producer:Linfen Qilin Pharmaceutical Co., Ltd. was established in 2003. The business scope of the company includes production, processing, wholesale and retail: tablets, hard capsules, granules, etc.
Staff size:100-199 persons
Registered capital:RMB 4 million
Producer:Yichang Sanxia Proudin Biopharmaceutical Co., Ltd.is a supplier committed to R & D and production of high-end amino acid series raw materials and preparations. The company's quality system is perfect. It has successively passed the GMP certification, HACCP quality management system certification, kosher and Halal certification of the State Food and drug administration. It is applying for the European Pharmacopoeia certificate. It is one of the drafting and formulation units of national drug standards for many amino acid products.
Staff size:200-299 persons
Registered capital:RMB 350 million
Producer:
Staff size:
Registered capital:RMB 50 million
Producer:Sinopharm Shantou Jinshi Pharmaceutical Co., Ltd. (formerly Shantou Jinshi Pharmaceutical General Factory) is now a wholly-owned subsidiary of Shanghai Modern Pharmaceutical Co., Ltd.
The enterprise covers an area of more than 36 Mu and a construction area of more than 20000 square meters. Its production scope includes chemical APIs, sterile APIs, tablets, hard capsules, powder injections, granules, dry suspensions, oral liquids and oral solutions. It has independently developed, developed and produced 154 approvals, including 142 preparations and 12 APIs; The Department and all its production lines (nine dosage forms and seven workshops in total) have passed the new version of GMP certification.
Staff size:400-499 persons
Registered capital:RMB 83.98 million
Producer:Yunpeng Pharmaceutical Group is a comprehensive high-tech enterprise integrating drug R & D, production, sales and logistics. It has 200 approval numbers, 9 subsidiaries and 1 branch, with a total asset value of 1.2 billion yuan. The group has a modern production base and R & D pilot base with chemical drugs, traditional Chinese medicine and API as the core, and the production lines have passed the new GMP certification.
The group has successively established business cooperation relations with India, Japan, Britain, South Korea and other countries, and its sales network is all over the world. At present, norfloxacin, indomethacin and mexiletine hydrochloride have been registered in India, and indomethacin has been registered in Russia, Mexico, Egypt, South Korea and other places. In Japan, mexiletine hydrochloride and vitamin U have also been reviewed by JDMF.
Staff size:
Registered capital:RMB 200 million
Producer:Yichang Sanxia Pharmaceutical Co., Ltd.is a wholly-owned subsidiary of humanwell Pharmaceutical Group. The company is a national high-tech enterprise. It is a comprehensive biopharmaceutical enterprise that studies and produces antibiotic API, amino acid series high-capacity injections and animal drug preparations.
The company is a large global supplier of neomycin sulfate API. Its subdivided product line covers neomycin sulfate for animals, Fraxinus sulfate, neomycin sulfate for prescription people in the United States, etc. its products have passed the certification of FDA and CEP of the European Union, with a global market share of more than 80%. Neomycin sulfate has won the title of "single champion product" in the national manufacturing industry. The company is also one of the earliest manufacturers of amino acid high-volume injections in China. At present, it mainly produces compound amino acid infusion and other basic infusion with product specifications of 3AA, 6Aa, 9aa, 15aa, 17aa, 17aa-i and 18AA, and the product specifications of various soft bags and glass bottles have reached 46. Among them, "Three Gorges brand" series amino acid high-volume injections are recognized as "famous brand products" and "high-quality products" in Hubei Province. The sales volume of compound amino acid injection 3AA accounts for more than 50% in China.
Staff size:1000-1999 persons
Registered capital:RMB 390 million
For supply and market information, please feel free to contact Mr. Paul, paulzhang@yinuopharmchem.com, WhatsApp: +86 18402846978
Tel: Cell/WhatsApp/WeChat: +86 18402846978
Email: paulzhang@yinuopharmchem.com
SKYPE